Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study.
Saved in:
| Title: | Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study. |
|---|---|
| Authors: | Verbeek MWC; Department of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands., Reiterová M; CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic., Laqua A; Department of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany., Rodríguez BS; Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.; Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain., Sedek L; Department of Microbiology and Immunology Medical University of Silesia Katowice Poland.; Department of Pediatric Hematology and Oncology Medical University of Silesia Katowice Poland., Buracchi C; Pediatrics, Fondazione IRCCS San Gerardo dei Tintori Monza Italy., Buysse M; Department of Diagnostic Sciences Ghent University Ghent Belgium.; Department of Laboratory Medicine Ghent University Hospital Ghent Belgium., Oliveira E; Faculty of Medicine Pediatrics Institute IPPMG Federal University of Rio de Janeiro Rio de Janeiro Brazil., Engelmann R; Clinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical Center Rostock Germany., Desterro J; Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto Lisboa Portugal., De Jong AX; Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands., Boettcher S; Clinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical Center Rostock Germany., Jugooa R; Department of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands., Barrena S; Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.; Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain., Kohlscheen S; Department of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany., Nierkens S; Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands., Rodriques JG; Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto Lisboa Portugal., Hofmans M; Department of Diagnostic Sciences Ghent University Ghent Belgium.; Department of Laboratory Medicine Ghent University Hospital Ghent Belgium., Gaipa G; Pediatrics, Fondazione IRCCS San Gerardo dei Tintori Monza Italy., Sobral de Costa E; Faculty of Medicine Pediatrics Institute IPPMG Federal University of Rio de Janeiro Rio de Janeiro Brazil., Mejstrikova E; CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic., Szczepanski T; Department of Pediatric Hematology and Oncology Medical University of Silesia Katowice Poland., Brüggemann M; Department of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany., van Dongen JJM; Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.; Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain.; Department of Immunology LUMC Leiden The Netherlands., Orfao A; Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.; Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain., van der Velden VHJ; Department of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands. |
| Source: | HemaSphere [Hemasphere] 2025 Apr 13; Vol. 9 (4), pp. e70125. Date of Electronic Publication: 2025 Apr 13 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2572-9241 |
|---|---|
| DOI: | 10.1002/hem3.70125 |
